Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7101866 | GLAXO GRP LTD | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
US7361787 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(1 year, 1 month ago) | |
USRE44874 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(1 year, 1 month ago) | |
US7439393 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(1 year, 26 days from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5873360 | GLAXO GRP LTD | Inhalation device |
Feb, 2016
(8 years ago) | |
US6759398 | GLAXO GRP LTD | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
US7629335 | GLAXO GRP LTD | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
US6878698 | GLAXO GRP LTD | Anti-inflammatory androstane derivatives |
Aug, 2021
(2 years ago) | |
US6537983 | GLAXO GRP LTD | Anti-inflammatory androstane derivatives |
Aug, 2021
(2 years ago) | |
US7776895 | GLAXO GRP LTD | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep, 2022
(1 year, 7 months ago) | |
US7439393 (Pediatric) | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
Nov, 2025
(1 year, 6 months from now) | |
US8511304 | GLAXO GRP LTD | Medicament dispenser |
Jun, 2027
(3 years from now) | |
US9333310 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2027
(3 years from now) | |
US8113199 | GLAXO GRP LTD | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
US8511304 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Dec, 2027
(3 years from now) | |
US8161968 | GLAXO GRP LTD | Medicament dispenser |
Feb, 2028
(3 years from now) | |
US9333310 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Apr, 2028
(3 years from now) | |
US8113199 (Pediatric) | GLAXO GRP LTD | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
US8161968 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Aug, 2028
(4 years from now) | |
US11116721 | GLAXO GRP LTD | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Feb, 2029
(4 years from now) | |
US11116721 (Pediatric) | GLAXO GRP LTD | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Aug, 2029
(5 years from now) | |
US8534281 | GLAXO GRP LTD | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
US8534281 (Pediatric) | GLAXO GRP LTD | Manifold for use in medicament dispenser |
Sep, 2030
(6 years from now) | |
US8746242 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2030
(6 years from now) | |
US8746242 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Apr, 2031
(6 years from now) |
Breo Ellipta is owned by Glaxo Grp Ltd.
Breo Ellipta contains Fluticasone Furoate; Vilanterol Trifenatate.
Breo Ellipta has a total of 25 drug patents out of which 9 drug patents have expired.
Expired drug patents of Breo Ellipta are:
Breo Ellipta was authorised for market use on 12 May, 2023.
Breo Ellipta is available in powder;inhalation dosage forms.
Breo Ellipta can be used as maintenance treatment of asthma in patients aged 5 years and older. recommended dosages: breo 100/25 or 200/25 ages 18 years and older; breo 100/25 ages 12-17 years, and breo 50/25, ages 5-11 years, indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older, indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations.
Drug patent challenges can be filed against Breo Ellipta from 13 November, 2025.
The generics of Breo Ellipta are possible to be released after 11 April, 2031.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | May 13, 2026 |
New Strength(NS) | May 13, 2026 |
Pediatric Exclusivity(PED) | Nov 13, 2026 |
M(M-202) | May 15, 2020 |
New Product(NP) | May 10, 2016 |
New Chemical Entity Exclusivity(NCE) | May 10, 2018 |
New Indication(I-708) | Apr 30, 2018 |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 13 November, 2025
Market Authorisation Date: 12 May, 2023
Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; Indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, includin...
Dosage: POWDER;INHALATION